Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases

Blood

Volumn 114, Issue 2, 2009, Pages 338-345

  Xu, Yibing ^a   Li, Jianwu ^a   Ferguson, Gregory D ^a   Mercurio, Frank ^a   Khambatta, Gody ^a   Morrison, Lisa ^a   Lopez Girona, Antonia ^a   Corral, Laura G ^a   Webb, David R ^a   Bennett, Brydon L ^a   Xie, Weilin ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

F ACTIN; INTERLEUKIN 2; LENALIDOMIDE; POMALIDOMIDE; PROTEIN CDC42; RAC1 PROTEIN; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ACTIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; THALIDOMIDE;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFECT; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; ANIMAL; CELL CULTURE; CELL MOTION; CYTOLOGY; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM;

ACTINS; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; CYTOSKELETON; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; MICE; MONOCYTES; RAC1 GTP-BINDING PROTEIN; RHOA GTP-BINDING PROTEIN; T-LYMPHOCYTES; THALIDOMIDE;

EID: 67651111993     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-200543     Document Type: Article

References (43)

1. Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med. 1996;2:506-515. (Pubitemid 26271704)
2. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999; 163:380-386.
3. Aragon-Ching JB, Li H, Gardner ER, Figg WD. Thalidomide analogues as anticancer drugs. Recent Patents Anticancer Drug Discov. 2007;2:167-174.
4. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322. (Pubitemid 38525287)
5. Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today. 2005;10:107-114.
6. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557.
7. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108: 3458-3464. (Pubitemid 44776887)
8. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26:2519-2525.
9. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291-5297.
10. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343-5349. (Pubitemid 46623164)
11. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008;26:1544-1552.
12. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res. 2006;30:849-858. (Pubitemid 43816707)
13. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67:746-755. (Pubitemid 46192215)
14. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103:1787-1790. (Pubitemid 38268973)
15. Payvandi F, Wu L, Naziruddin SD, et al. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-θ activation and enhancing the DNA-binding activity of AP-1 but not NF-κB, OCT-1, or NF-AT. J Interferon Cytokine Res. 2005;25:604-616. (Pubitemid 41507816)
16. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunologic synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427-2437.
17. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629-635.
18. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247-269.
19. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A. 2004;101:7618-7623. (Pubitemid 38658078)
20. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-514.
21. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rhoassociated protein kinase in hypertension. Nature. 1997;389:990-994. (Pubitemid 27485693)
22. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science. 2003;302:1704-1709. (Pubitemid 37505725)
23. Gardiner EM, Pestonjamasp KN, Bohl BP, Chamberlain C, Hahn KM, Bokoch GM. Spatial and temporal analysis of Rac activation during live neutrophil chemotaxis. Curr Biol. 2002;12: 2029-2034. (Pubitemid 35450926)
24. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446-456. (Pubitemid 36648590)
25. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signaling. Nat Rev Immunol. 2003;3:939-951. (Pubitemid 37521536)
26. Gomez M, Tybulewicz V, Cantrell DA. Control of pre-T cell proliferation and differentiation by the GTPase Rac-I. Nat Immunol. 2000;1:348-352.
27. Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003;305:1222-1232.
28. Anderson KC. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol. 2005;42:S3-S8.
29. Xu W, Celeridad M, Sankar S, Webb DR, Bennett BL. CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet. Clin Immunol. 2008;128:392-399.
30. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood. 1984;63:305-309.
31. Maki G, Hayes GM, Naji A, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia. 2008;22:998-1006. (Pubitemid 351689882)
32. Ziegler HW, Kay NE, Zarling JM, et al. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer. 1981;27:321-327. (Pubitemid 11155351)
33. Jewell AP, Worman CP, Giles FJ, Goldstone AH, Lydyard PM. Resistance of chronic lymphocytic leukaemia cells to interferon-α generated lymphokine activated killer cells. Leuk Lymphoma. 1992;7:473-480.
34. Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, Eliopoulos GD. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-α. Acta Haematol. 1996;96:16-23. (Pubitemid 26187968)
35. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140:36-45. (Pubitemid 350233246)
36. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008;26:1544-1552.
37. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
38. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128:192-203.
39. Lang P, Guizani L, Vitte-Mony I, et al. ADP-ribosylation of the ras-related, GTP-binding protein RhoA inhibits lymphocyte-mediated cytotoxicity. J Biol Chem. 1992;267:11677-11680.
40. Woodside DG, Wooten DK, McIntyre BW. Adenosine diphosphate (ADP)-ribosylation of the guanosine triphosphatase (GTPase) rho in resting peripheral blood human T lymphocytes results in pseudopodial extension and the inhibition of T cell activation. J Exp Med. 1998;188:1211-1221.
41. Angkachatchai V, Finkel TH. ADP-ribosylation of rho by C3 ribosyltransferase inhibits IL-2 production and sustained calcium influx in activated T cells. J Immunol. 1999;163:3819-3825. (Pubitemid 29450907)
42. Burkhardt JK, Carrizosa E, Shaffer MH. The actin cytoskeleton in T cell activation. Annu Rev Immunol. 2008;26:233-259.
43. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science. 1999;285:221-227. (Pubitemid 29329988)